DK3834841T3 - Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer - Google Patents

Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer Download PDF

Info

Publication number: DK3834841T3
Authority: DK; Denmark
Prior art keywords: stabilized liquid; adamts13 formulations; lyophilized adamts13; lyophilized; formulations
Prior art date: 2009-09-21

Application number

DK20211228.0T

Other languages

English (en)

Inventor

H Peter Matthiessen

Peter Turecek

Hans-Peter Schwarz

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-21

Filing date

2010-09-21

Publication date

2023-06-06

2010-09-21 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2023-06-06 Application granted granted Critical

2023-06-06 Publication of DK3834841T3 publication Critical patent/DK3834841T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Dispersion Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK20211228.0T 2009-09-21 2010-09-21 Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer DK3834841T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24435309P	2009-09-21	2009-09-21
EP15203085.4A EP3167897B1 (en)	2009-09-21	2010-09-21	Stabilized liquid and lyophilized adamts13 formulations

Publications (1)

Publication Number	Publication Date
DK3834841T3 true DK3834841T3 (da)	2023-06-06

Family

ID=43598388

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK15203085.4T DK3167897T3 (da)	2009-09-21	2010-09-21	Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer
DK10759786.6T DK2480198T3 (da)	2009-09-21	2010-09-21	Stabiliserede væskeformige- og lyofiliserede adamts13-formuleringer
DK20211228.0T DK3834841T3 (da)	2009-09-21	2010-09-21	Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer
DK23172759.5T DK4218797T5 (da)	2009-09-21	2010-09-21	Stabiliseret væske og frysetørrede adamts13-formuleringer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK15203085.4T DK3167897T3 (da)	2009-09-21	2010-09-21	Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer
DK10759786.6T DK2480198T3 (da)	2009-09-21	2010-09-21	Stabiliserede væskeformige- og lyofiliserede adamts13-formuleringer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK23172759.5T DK4218797T5 (da)	2009-09-21	2010-09-21	Stabiliseret væske og frysetørrede adamts13-formuleringer

Country Status (21)

Country	Link
US (9)	US8623352B2 (da)
EP (5)	EP4467160A3 (da)
JP (2)	JP5819303B2 (da)
KR (6)	KR20210054598A (da)
CN (2)	CN102573792B (da)
AU (1)	AU2010295299B2 (da)
BR (1)	BR112012006283B1 (da)
CA (1)	CA2774556A1 (da)
DK (4)	DK3167897T3 (da)
EA (1)	EA024267B1 (da)
ES (4)	ES2865250T3 (da)
FI (2)	FI3834841T3 (da)
FR (1)	FR24C1049I2 (da)
HR (1)	HRP20160295T1 (da)
HU (1)	HUE028688T2 (da)
IN (1)	IN2012DN02645A (da)
MX (3)	MX339205B (da)
NZ (1)	NZ598839A (da)
PL (4)	PL3167897T3 (da)
PT (2)	PT4218797T (da)
WO (1)	WO2011035335A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2745805C (en)	2008-12-05	2021-01-19	Baxter International Inc.	Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
KR20210054598A (ko) *	2009-09-21	2021-05-13	다케다 야쿠힌 고교 가부시키가이샤	안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
IN2014MN01642A (da) *	2012-02-16	2015-07-03	Atyr Pharma Inc
CN103566362B (zh) *	2012-07-21	2015-07-29	复旦大学	重组adamts13在制备脑出血药物中的用途
US10441531B2 (en) *	2012-11-09	2019-10-15	Bloodworks	Protein stabilizing factors
AU2013203062C1 (en) *	2013-03-15	2018-06-28	Takeda Pharmaceutical Company Limited	Subcutaneous administration of adamts13
US9587235B2 (en)	2013-03-15	2017-03-07	Atyr Pharma, Inc.	Histidyl-tRNA synthetase-Fc conjugates
CA2952609A1 (en) *	2014-06-26	2015-12-30	Amgen Inc.	Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
GB201510870D0 (en) *	2015-05-26	2015-08-05	Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh	Treatment of infarction
ES2983978T3 (es) *	2016-01-08	2024-10-28	Univ Kyoto	Medicina que comprende ADAMTS13 como ingrediente principal
EA201990373A1 (ru) *	2016-08-04	2019-07-31	Баксалта Инкорпорэйтед	Применение adamts13 для лечения, уменьшения интенсивности и/или предупреждения вазоокклюзивного криза при серповидноклеточной анемии, остром повреждении легкого и/или остром респираторном дистресс-синдроме
PT3534922T (pt)	2016-11-04	2024-06-07	Takeda Pharmaceuticals Co	Formulações de vírus adenoassociado
CN110536694A (zh)	2017-04-20	2019-12-03	Atyr 医药公司	用于治疗肺部炎症的组合物和方法
PL3639845T3 (pl) *	2017-07-25	2023-10-23	Jiangsu Hengrui Medicine Co., Ltd.	Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
AU2019299964A1 (en) *	2018-07-11	2021-01-21	Takeda Pharmaceutical Company Limited	AAV compositions
EP4037704B1 (en)	2019-10-04	2025-12-03	The Children's Medical Center Corporation	Adamts13 treatment to enhance graft survival
AU2021248679A1 (en)	2020-04-02	2022-10-27	Takeda Pharmaceutical Company Limited	ADAMTS13 variant, compositions, and uses thereof
EP4153215A1 (en)	2020-05-22	2023-03-29	Takeda Pharmaceutical Company Limited	Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
EP4196147A4 (en) *	2020-08-13	2024-08-21	Hadasit Medical Research Services and Development Ltd.	DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, MUTANTS OF ELEMENT 13 (ADAMTS-13), COMPOSITIONS AND THERAPEUTIC METHODS THEREFOR
WO2023170680A1 (en)	2022-03-08	2023-09-14	Equashield Medical Ltd	Fluid transfer station in a robotic pharmaceutical preparation system
KR20240112755A (ko) *	2023-01-11	2024-07-19	주식회사 녹십자	혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5250421A (en)	1986-01-03	1993-10-05	Genetics Institute, Inc.	Method for producing factor VIII:C-type proteins
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en)	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de)	1997-06-20	2001-02-26	Immuno Ag	Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en)	1997-06-20	2002-11-05	Baxter Aktiengesellschaft	Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2634663C (en)	1999-02-22	2009-08-25	University Of Connecticut	Novel albumin-free factor viii formulations
JP2001227510A (ja)	2000-02-15	2001-08-24	Tomoe Tech Res Co	複作動型の空気式アクチュエータ
JP3783507B2 (ja)	2000-02-16	2006-06-07	日本精工株式会社	トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en)	2000-11-22	2005-08-09	Baxter Aktiengesellschaft	Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) *	2001-04-25	2003-10-07	Chemo Sero Therapeut Res Inst	フォンビルブラント因子（ｖＷＦ）切断酵素
AU2002336367A1 (en) *	2001-08-16	2003-03-03	The Regents Of The University Of Michigan	Adamts13 genes and proteins and variants, and uses thereof
ITPR20010055A1 (it)	2001-08-31	2003-03-03	Vetroarredo Spa	Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko)	2002-10-09	2005-03-10	동부아남반도체 주식회사	모스 트랜지스터 제조 방법
US7780831B2 (en) *	2003-07-07	2010-08-24	The University Of North Carolina At Chapel Hill	Assays for detection of von willebrand factor (vWF) multimers and for degradation of vWF by agents such as ADAMTS13 and related methods
GB0404693D0 (en) *	2004-03-02	2004-04-07	Univ London	Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en)	2004-10-29	2006-05-04	Leopold Grillberger	Animal protein-free media for cultivation of cells
AU2006257073B2 (en)	2005-06-17	2011-08-04	Children's Medical Center Corporation	ADAMTS13-comprising compositions having thrombolytic activity
JP4880997B2 (ja) *	2005-12-28	2012-02-22	アルフレッサファーマ株式会社	Ａｄａｍｔｓ１３の安定化方法
SI2522717T1 (sl)	2006-01-04	2014-05-30	Baxter International Inc.	Mediji celične kulture brez oligopeptidov
KR20210054598A (ko) *	2009-09-21	2021-05-13	다케다 야쿠힌 고교 가부시키가이샤	안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
US8823352B2 (en)	2011-07-11	2014-09-02	Linear Technology Corporation	Switching power supply having separate AC and DC current sensing paths

2010
- 2010-09-21 KR KR1020217013486A patent/KR20210054598A/ko not_active Ceased
- 2010-09-21 PL PL15203085T patent/PL3167897T3/pl unknown
- 2010-09-21 NZ NZ598839A patent/NZ598839A/en unknown
- 2010-09-21 EP EP24192531.2A patent/EP4467160A3/en active Pending
- 2010-09-21 HU HUE10759786A patent/HUE028688T2/en unknown
- 2010-09-21 KR KR1020227034508A patent/KR20220139456A/ko not_active Ceased
- 2010-09-21 PL PL23172759.5T patent/PL4218797T3/pl unknown
- 2010-09-21 KR KR1020247043292A patent/KR20250008986A/ko not_active Ceased
- 2010-09-21 DK DK15203085.4T patent/DK3167897T3/da active
- 2010-09-21 ES ES15203085T patent/ES2865250T3/es active Active
- 2010-09-21 WO PCT/US2010/049723 patent/WO2011035335A2/en not_active Ceased
- 2010-09-21 EP EP23172759.5A patent/EP4218797B9/en active Active
- 2010-09-21 JP JP2012529982A patent/JP5819303B2/ja active Active
- 2010-09-21 FI FIEP20211228.0T patent/FI3834841T3/fi active
- 2010-09-21 MX MX2012003414A patent/MX339205B/es active IP Right Grant
- 2010-09-21 PL PL10759786.6T patent/PL2480198T3/pl unknown
- 2010-09-21 DK DK10759786.6T patent/DK2480198T3/da active
- 2010-09-21 EP EP20211228.0A patent/EP3834841B1/en active Active
- 2010-09-21 MX MX2016005314A patent/MX362382B/es unknown
- 2010-09-21 DK DK20211228.0T patent/DK3834841T3/da active
- 2010-09-21 ES ES23172759T patent/ES3001509T3/es active Active
- 2010-09-21 CA CA2774556A patent/CA2774556A1/en not_active Abandoned
- 2010-09-21 HR HRP20160295TT patent/HRP20160295T1/hr unknown
- 2010-09-21 KR KR1020127009803A patent/KR101891646B1/ko active Active
- 2010-09-21 EA EA201200519A patent/EA024267B1/ru not_active IP Right Cessation
- 2010-09-21 AU AU2010295299A patent/AU2010295299B2/en active Active
- 2010-09-21 ES ES10759786.6T patent/ES2579906T3/es active Active
- 2010-09-21 US US12/887,424 patent/US8623352B2/en active Active
- 2010-09-21 KR KR1020187023806A patent/KR20180095738A/ko not_active Ceased
- 2010-09-21 IN IN2645DEN2012 patent/IN2012DN02645A/en unknown
- 2010-09-21 BR BR112012006283-2A patent/BR112012006283B1/pt active IP Right Grant
- 2010-09-21 FI FIEP23172759.5T patent/FI4218797T3/fi active
- 2010-09-21 PT PT231727595T patent/PT4218797T/pt unknown
- 2010-09-21 DK DK23172759.5T patent/DK4218797T5/da active
- 2010-09-21 PL PL20211228.0T patent/PL3834841T3/pl unknown
- 2010-09-21 ES ES20211228T patent/ES2948612T3/es active Active
- 2010-09-21 PT PT202112280T patent/PT3834841T/pt unknown
- 2010-09-21 EP EP15203085.4A patent/EP3167897B1/en active Active
- 2010-09-21 EP EP10759786.6A patent/EP2480198B9/en active Active
- 2010-09-21 CN CN201080046707.6A patent/CN102573792B/zh active Active
- 2010-09-21 CN CN201410452647.8A patent/CN104224705B/zh active Active
- 2010-09-21 KR KR1020197035791A patent/KR20190137954A/ko not_active Ceased
2012
- 2012-03-21 MX MX2019000547A patent/MX2019000547A/es unknown
2013
- 2013-11-22 US US14/088,169 patent/US9351935B2/en active Active
2014
- 2014-12-24 JP JP2014259954A patent/JP2015063556A/ja active Pending
2016
- 2016-05-03 US US15/145,755 patent/US9572778B2/en active Active
2017
- 2017-01-06 US US15/400,526 patent/US9937244B2/en active Active
2018
- 2018-02-28 US US15/908,213 patent/US10238720B2/en active Active
2019
- 2019-02-14 US US16/275,690 patent/US10758599B2/en active Active
2020
- 2020-07-21 US US16/934,100 patent/US11564979B2/en active Active
2022
- 2022-12-23 US US18/146,212 patent/US12178861B2/en active Active
2024
- 2024-11-19 US US18/952,409 patent/US20250099559A1/en active Pending
- 2024-12-10 FR FR24C1049C patent/FR24C1049I2/fr active Active

Also Published As

Publication number	Publication date
EP3167897B1 (en)	2021-01-27
EA201200519A1 (ru)	2012-09-28
EP3834841B1 (en)	2023-05-17
KR20190137954A (ko)	2019-12-11
PT3834841T (pt)	2023-06-19
BR112012006283A2 (pt)	2016-05-31
HUE028688T2 (en)	2017-01-30
EP4218797A1 (en)	2023-08-02
KR20180095738A (ko)	2018-08-27
EP4467160A2 (en)	2024-11-27
EP4218797B1 (en)	2024-09-11
FR24C1049I1 (fr)	2025-01-17
JP2013505270A (ja)	2013-02-14
KR20120099646A (ko)	2012-09-11
ES3001509T3 (en)	2025-03-05
WO2011035335A3 (en)	2011-12-01
PT4218797T (pt)	2024-12-09
US20170112906A1 (en)	2017-04-27
CN102573792B (zh)	2014-10-15
KR101891646B1 (ko)	2018-08-27
FI3834841T3 (fi)	2023-06-05
PL2480198T3 (pl)	2016-09-30
ES2948612T3 (es)	2023-09-14
HK1173968A1 (zh)	2013-05-31
US9937244B2 (en)	2018-04-10
US10238720B2 (en)	2019-03-26
PL3167897T3 (pl)	2021-09-27
ES2579906T3 (es)	2016-08-17
EP2480198B1 (en)	2016-03-09
US9351935B2 (en)	2016-05-31
US20230130866A1 (en)	2023-04-27
US9572778B2 (en)	2017-02-21
US20160375111A1 (en)	2016-12-29
CA2774556A1 (en)	2011-03-24
US11564979B2 (en)	2023-01-31
EP3167897A1 (en)	2017-05-17
NZ598839A (en)	2014-03-28
BR112012006283B1 (pt)	2022-03-15
MX2019000547A (es)	2020-11-12
EP2480198A2 (en)	2012-08-01
MX362382B (es)	2019-01-14
DK2480198T3 (da)	2016-03-29
PL3834841T3 (pl)	2023-07-24
CN102573792A (zh)	2012-07-11
CN104224705A (zh)	2014-12-24
DK4218797T3 (da)	2024-12-09
PL4218797T3 (pl)	2025-02-10
DK3167897T3 (da)	2021-04-19
EP3834841A1 (en)	2021-06-16
EP4218797B9 (en)	2025-04-30
US8623352B2 (en)	2014-01-07
JP5819303B2 (ja)	2015-11-24
US20190247475A1 (en)	2019-08-15
MX2012003414A (es)	2012-06-19
DK4218797T5 (da)	2025-07-21
US20110229455A1 (en)	2011-09-22
FI4218797T3 (fi)	2024-12-07
WO2011035335A2 (en)	2011-03-24
JP2015063556A (ja)	2015-04-09
US20180207245A1 (en)	2018-07-26
US10758599B2 (en)	2020-09-01
KR20210054598A (ko)	2021-05-13
US20200376098A1 (en)	2020-12-03
US20140178357A1 (en)	2014-06-26
CN104224705B (zh)	2018-02-02
ES2865250T3 (es)	2021-10-15
FR24C1049I2 (fr)	2025-12-12
IN2012DN02645A (da)	2015-09-11
EP4467160A3 (en)	2025-01-15
US12178861B2 (en)	2024-12-31
AU2010295299B2 (en)	2015-12-24
EP2480198B9 (en)	2016-11-23
AU2010295299A1 (en)	2012-04-12
KR20220139456A (ko)	2022-10-14
EA024267B1 (ru)	2016-09-30
HRP20160295T1 (hr)	2016-05-20
US20250099559A1 (en)	2025-03-27
KR20250008986A (ko)	2025-01-16
MX339205B (es)	2016-05-16

Publication	Publication Date	Title
DK4218797T5 (da)	2025-07-21	Stabiliseret væske og frysetørrede adamts13-formuleringer
SMT201600319B (it)	2016-11-10	Metodi di selezione e amplificazione di polinucleotidi
BRPI0907231A2 (pt)	2019-09-24	pirrolpirimidinas e pirrolpiridinas
DK2648742T3 (da)	2019-07-15	Formuleringer indeholdende saponiner og anvendelser deraf
HRP20181347T1 (hr)	2018-10-19	Formulacije dvoslojne tablete
PL2477638T3 (pl)	2018-12-31	Stabilizacja probiotyku
HRP20160737T1 (hr)	2016-07-15	Anti-her3-protutijela i njihove uporabe
EP2449102A4 (en)	2013-01-02	ARGINASE FORMULATIONS AND METHODS
BRPI1014160A2 (pt)	2015-08-25	Formulações de nanopartículas e aplicações das mesmas
HRP20160579T1 (hr)	2016-07-29	Spoj indola i njegova farmaceutska upotreba
LT2419732T (lt)	2020-03-10	Prionų neturinčios nanodalelių kompozicijos ir būdai
DK2504353T4 (da)	2023-11-20	Lipopeptidsammensætninger og tilsvarende fremgangsmåder
DK2600715T3 (da)	2020-03-16	Flydende ST-246-formuleringer og fremgangsmåder
DK2805746T3 (da)	2020-08-10	Alkylamido-forbindelser og anvendelser deraf
BRPI1008270A2 (pt)	2016-03-15	aparelho e sistema
DK2086213T3 (da)	2010-10-18	Billedlæseapparat og billeddannelseapparat
DK2475649T3 (da)	2014-11-03	Indenonderivat og farmaceutisk sammensætning omfattende samme
BRPI1008887A2 (pt)	2016-03-01	peptídeos de foxm1 e vacinas contendo os mesmo
FI20095636A0 (fi)	2009-06-08	Näyttöjärjestelmä ja -laite
IL229926A (en)	2016-11-30	Neil3 peptides and vaccines including the same
HUE054030T2 (hu)	2021-08-30	Fejlesztett formulációk
DK2406372T3 (da)	2017-11-27	Prægastrisk esterase og derivater deraf
EP2442827A4 (en)	2013-04-17	NANO EMULSION VACCINES
EP2475430A4 (en)	2013-05-15	GRANULATED ANTHELMINTIC PREPARATIONS AND OUTPUT SYSTEMS THEREFOR
BRPI1014810A2 (pt)	2015-08-25	Métodos e formulações ectoparasiticidas